Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

evir is being studied in combination with pegylated interferon and ribavirin, and in combination with direct-acting antiviral (DAA) agents in all-oral interferon-free regimens, with and without ribavirin.

Global Phase 3 studies of simeprevir include QUEST-1 and QUEST-2 in treatment-naive patients, PROMISE in patients who have relapsed after prior interferon-based treatment and ATTAIN in treatment-experienced patients. In parallel to these trials, Phase 3 studies for simeprevir are ongoing in both treatment-naive and treatment-experienced HIV-HCV co-infected patients, HCV genotype 4 patients and in Japanese HCV genotype 1 patients.

Simeprevir is also being studied in other Phase 2 interferon-free trials, with and without ribavirin, in combination with:

  • Janssen's TMC647055 and ritonavir in treatment-naive, relapser or null-responder HCV genotype 1 patients;
  • Gilead Sciences, Inc.'s sofosbuvir (GS-7977) in null-responder HCV genotype 1 patients; and
  • Bristol-Myers Squibb's daclatasvir (BMS-790052) in treatment-naive or previous null-responder HCV genotype 1 patients.

For additional information about simeprevir, please visit www.clinicaltrials.gov.

About Hepatitis C
Hepatitis C, a blood-borne infectious disease of the liver and a leading cause of chronic liver disease and liver transplants, is a rapidly evolving treatment area with a clear need for innovative treatments. Approximately 170 to 210 million people are infected with hepatitis C worldwide, with three to four million people newly infected each year.

About Janssen
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in infectious diseases and vaccines, oncology, immunology, neuroscience, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative product
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , September 22, 2014 ... New Market Report on "Global Market Study on Ophthalmic ... Growth by 2020," the global ophthalmic devices market was valued at ... grow at a CAGR of 6.5% from 2014 to ... million in 2020. Browse the full Global Market ...
(Date:9/22/2014)... , Sept. 22, 2014  AVT, Inc. (OTC ... retailing systems and custom vending machines, announced today that ... Unit. This new, smaller sized unit is designed for ... practices. According to industry statistics, there are ... Opticwash is the world,s first automated kiosk ...
(Date:9/22/2014)... GERMANTOWN, Md. , Sept. 22, 2014  Neuralstem, Inc. ... , MD, site investigator at Emory University, presented long-term ... NSI-566 human neural stem cells in the treatment of ... disease).  The presentation, which occurred at the Annual Symposium ... Montreal, Canada , on Friday, and was not ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Opticwash Pro Enables Optical Retailers to Generate New Revenues and Customer Traffic through a Unique Eyeglass Cleaning System 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... -- Recent two-generation approaches to reducing poverty that ... attention from researchers, advocates, and foundations. By combining ... to move to jobs that offer a path ... education for children, these programs aim to improve ... to a new report from the National Center ...
(Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pain does not ... Pain” is a user- and reader-friendly book designed to guide ... to pain-free living. This inspirational book is written to help ... to know a way to regain a pain-free life — ... of chronic pain. , Chronic pain has become an epidemic, ...
(Date:9/22/2014)... 2014) Montefiore Medical Center, Albert Einstein College of Medicine ... received a $300,000 grant from The Agency for Healthcare ... health Information Technology (IT) on patient safety. , This ... important clinical patient safety issue impacted by health IT. ... first time IT leaders have data on the risk ...
Breaking Medicine News(10 mins):Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2Health News:AHRQ grant awarded to study the impact of health IT on patient safety at Montefiore and Einstein and Brigham and Women's Hospital 2
... 23 NxStage Medical, Inc.,(Nasdaq: NXTM ), a ... million private placement of its common stock and,warrants. The ... stock at a price of $4.50 per share and ... an exercise price of $5.50 per share,which price may ...
... 23 Dr. Nancy Minshew, a,leading researcher on the ... work in a presentation co-sponsored by the Pennsylvania,Cyber Charter ... diagnosed with autism. Students with,autism and other special needs ... its mission, is committed to focusing on the needs ...
... University,Medical Center (MUMC) now offers a type of ... the belly button. It,s called single,incision laparoscopic surgery, ... in the SILS technique. One of them is ... remove the gallbladder through a,1cm. incision in the ...
... MDNG, a publication that,reaches nearly a quarter ... discussion that will provide physicians an opportunity,to speak ... unique,practice model has made him a household name. ... 2008, at 8:00 p.m. EDT at, http://www.mdnglive.com/chat/JayParkinson ., ...
... 500,000 to make a world of difference for Singer Songwriter Katie ... Reider Beginning ... years, Cincinnati-based,singer songwriter Katie Reider, age 29, has inspired the hearts ... within. Fans across the country are banding together to help Katie,during ...
... ... health in the Western world, the, Omega-3 story may someday be viewed ... - William S. Harris, PhD, American ... Nutrition (2003), COLUMBUS, Ohio, May 23 If anyone needed another reason,to ...
Cached Medicine News:Health News:NxStage Announces $43 Million Private Placement of Equity Securities 2Health News:NxStage Announces $43 Million Private Placement of Equity Securities 3Health News:NxStage Announces $43 Million Private Placement of Equity Securities 4Health News:Dr. Nancy Minshew, Autism Researcher, to Speak at Regional Learning Alliance in Cranberry Township 2Health News:SILS Surgical Technique Now Available at MUMC 2Health News:MDNG Offers Free Online Discussion With Maverick Physician Jay Parkinson, M.D. 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 2Health News:Katie Reider - Listen to Her Songs, Hear Her Story, Log Onto www.500kin365.org 3Health News:Announcing Another Great Reason to Eat Chocolate 2
Fixed smooth rod which slides on skin. Designated most popular model or size....
Grooved roller, on which knife oscillates....
Disposable. For use with the N4086....
30 mm button end blade. Flat handle....
Medicine Products: